« Back
Construction and Characterization of an HIV DNA-VLP Vaccine Using Bacteriophage λ
Poster Title: Construction and Characterization of an HIV DNA-VLP Vaccine Using Bacteriophage λ
Submitted on 17 Jan 2017
Author(s): Jessica Nicastro and Roderick Slavcev
Affiliations: University of Waterloo, School of Pharmacy
This poster was presented at Bacteriophage 2017
Poster Views: 1,459
View poster »

Poster Information
Abstract: Bacteriophage (phage), or bacterial viruses, have been exploited for “phage display”, the engineered expression of a peptide of interest fused to the coat protein of a tolerant phage. The lytic phage λ has effective phage display capability which we have previously exploited to construct a tuneable peptide display platform for superior fusion tolerance and functionality.
Hybrid phage gene delivery vehicles were constructed from specialized λF7, a nanophage derivative used to display HIV TAT. TAT is a cell-penetrating peptide that dramatically increases transfection efficiency by binding CD51/61 surface receptors to target and specifically enhance transgene delivery. A specialized eGFP construct was subcloned into a eukaryotic expression vector to ensure mammalian host expression. DNA encapsulation, including the the extent of DNA degradation, was assessed through DNase sensitivity assays with respect to pH, temperature and time.
Isogenic K568 derivatives with or without CD51/61 surface expression will be transfected with the phage vectors possessing the eGFP expression cassette with or without surface TAT decoration. Transfection efficiency conferred by the hybrid phage construct will be assessed and further optimized by flow cytometry for evidence of eGFP expression as the GOI and by immunoblot for evidence of eGFP protein expression.
The small size, structural versatility, and relative ease of genome isolation of phage combination of a highly tunable phage display system in combination with the intrinsic advantages of phage-based delivery allow for the development “hybrid phages” which are quite distinct from other leading platforms in the nanotechnology field and offer strong applications to agriculture and medicine.
Summary: Construction and characterization of a DNA HIV-VLP vaccine using bacteriophage λReport abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

Multiplex miRNA Profiling for Biomarker Discovery and Verification Studies Using the FirePlex® Platform
M. Tackett, B. Heinrich, I. Diwan, G. Tejada, C. Rafferty, E. Atabakhsh, and D. Pregibon

Accelerating high-throughput screening with FirePlex®-HT:An automatable, multiplex immunoassay using FirePlex® Particle Technology
A. Perea, B. Heinrich, W. Austin, C. Rafferty, M. Camilleri, L. To, E. Atabakhsh, and D. Pregibon

Platinum™ SuperFi™ DNA Polymerase for the highest success in PCR
Rasa Sukackaitė, Martyna Simutytė, Skaistė Valinskytė, Laurynas Vanagas, Karolis Matjošaitis, Renata Rimšelienė, Remigijus Skirgaila.

DNA-free Platinum Taq DNA polymerase for reliable microbiome studies
Kęstutis Bargaila, Vytautas Budrys, Andrius Krasauskas, Dovilė Lisauskienė, Milda Romeikaitė, Sonata Jurėnaitė-Urbanavičienė,Ramunė Leipuvienė and Juozas Šiurkus

riboPOOL: Affordable Custom/Ribosomal RNA Depletion Against Any Species for RNA-Seq
Catherine Goh1, Andrew Walsh1, Michaela Beitzinger1, Jonas Bertram1, Kristina Döring3, Sascha Dietrich3, Iana Kim4, Stefan Kotschote2, Claus Kuhn4, Konrad Förstner3, Michael Bonin2, Stefan Hannus1, Michael Hannus1